Simvastatin interactions with other drugs

Expert Opinion on Drug Safety

Volumn 11, Issue 3, 2012, Pages 439-444

  Florentin, Matilda ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cytochrome P450; Interactions; Rhabdomyolysis; Simvastatin

Indexed keywords

AMIODARONE; AMLODIPINE; ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DANAZOL; DILTIAZEM; DRONEDARONE; ERYTHROMYCIN; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NEFAZODONE; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; POSACONAZOLE; PRAVASTATIN; RANOLAZINE; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TELITHROMYCIN; TICAGRELOR; UNINDEXED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCURONIDATION; GRAPEFRUIT JUICE; HEART ATRIUM FIBRILLATION; HEART MUSCLE INJURY; HEPATITIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MYALGIA; MYOPATHY; MYOSITIS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STABLE ANGINA PECTORIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN;

EID: 84860174356     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.670633     Document Type: Review

References (46)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
2. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm [Last accessed 26 December 2011]
3. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7 (Pubitemid 38786444)
4. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81 (Pubitemid 44908269)
5. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006;26:1601-7 (Pubitemid 44704473)
6. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
7. Xia CQ, Yang JJ, Gan LS. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 2005;1:595-611
8. Takeda M, Noshiro R, Onozato ML, et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 2004;483:133-8 (Pubitemid 38068393)
9. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72 (Pubitemid 34833176)
10. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403
11. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:S52-60
12. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9 (Pubitemid 30659167)
13. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51 (Pubitemid 34595097)
14. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94:1140-6 (Pubitemid 39424216)
15. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658-69
16. Lasocki A, Vote B, Fassett R, et al. Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. Ocul Immunol Inflamm 2007;15:345-6 (Pubitemid 47347034)
17. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can J Clin Pharmacol 2003;10:172-4 (Pubitemid 38181967)
18. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005;39:307-12 (Pubitemid 40923210)
19. Cheng CH, Miller C, Lowe C, et al. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002;59:728-30 (Pubitemid 34407159)
20. FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone. Available from: http://www. fda.gov/Drugs/DrugSafety/ucm283137.htm [Last accessed 26 December 2011]
21. Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000;67:267-74 (Pubitemid 30176385)
22. Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001;94:339-41
23. Hu M, Mak VW, Tomlinson B. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. J Clin Pharm Ther 2011;36:419-25
24. Nishio S, Watanabe H, Kosuge K, et al. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005;28:223-7 (Pubitemid 40812606)
25. Park CG, Lee H, Choi JW, et al. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther 2010;48:497-503
26. Marot A, Morelle J, Chouinard VA, et al. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 2011;66:134-6
27. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005;45:422-33 (Pubitemid 40490415)
28. Hylton AC, Ezekiel TO. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. Am J Health Syst Pharm 2010;67:1829-31
29. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82 (Pubitemid 28423853)
30. Bhindi R, Ormerod O, Newton J, et al. Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 2008;101:915-25
31. Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Des 2006;12:1271-80 (Pubitemid 44082136)
32. Gulec S, Ozdol C, Rahimov U, et al. Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction. J Invasive Cardiol 2005;17:589-93
33. Serrano Junior CV, Soeiro Ade M, Araujo LF, et al. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation. Arq Bras Cardiol 2010;95:321-7
34. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-5 (Pubitemid 47058889)
35. Giorgi MA, Di Girolamo G, Gonzalez CD. Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin Pharmacother 2010;11:2391-403
36. Brilique, INN-ticagrelor. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/EPARProduct Information/human/001241/WC500100494.pdf [Last accessed 18 December 2011]
37. Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia 2008;63:656-8 (Pubitemid 351677317)
38. Sawant RD. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol 2009;16:e78-9
39. Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med J 2003;96:1034-5
40. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 2008;9:232-4
41. Dopazo C, Bilbao I, Lazaro JL, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant Proc 2009;41:1021-4
42. Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother 2007;41:1292-5 (Pubitemid 47122570)
43. Ayalasomayajula SP, Dole K, He YL, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007;23:2913-20
44. Krishna R, Garg A, Jin B, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009;67:520-6
45. Derks M, Abt M, Phelan M, et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010;50:1188-201
46. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009;48:39-50